ATE555794T1 - Heilmittel gegen hepatitis - Google Patents

Heilmittel gegen hepatitis

Info

Publication number
ATE555794T1
ATE555794T1 AT01904385T AT01904385T ATE555794T1 AT E555794 T1 ATE555794 T1 AT E555794T1 AT 01904385 T AT01904385 T AT 01904385T AT 01904385 T AT01904385 T AT 01904385T AT E555794 T1 ATE555794 T1 AT E555794T1
Authority
AT
Austria
Prior art keywords
hepatitis
remedies
virus
present
cell
Prior art date
Application number
AT01904385T
Other languages
English (en)
Inventor
Seima Itami
Tatsurou Shibui
Makoto Seki
Yoshihisa Yotsumoto
Yoshiharu Matsuura
Tatsuo Miyamura
Original Assignee
Mitsubishi Tanabe Pharma Corp
Jp Agency Of Nat Inst Of Infectious Deseases
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp, Jp Agency Of Nat Inst Of Infectious Deseases filed Critical Mitsubishi Tanabe Pharma Corp
Application granted granted Critical
Publication of ATE555794T1 publication Critical patent/ATE555794T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C07K16/118—Hepatitis C virus; GB virus C [GBV-C]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01904385T 2000-02-14 2001-02-13 Heilmittel gegen hepatitis ATE555794T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000034906 2000-02-14
PCT/JP2001/000967 WO2001058459A1 (fr) 2000-02-14 2001-02-13 Remedes contre l'hepatite c

Publications (1)

Publication Number Publication Date
ATE555794T1 true ATE555794T1 (de) 2012-05-15

Family

ID=18559171

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01904385T ATE555794T1 (de) 2000-02-14 2001-02-13 Heilmittel gegen hepatitis

Country Status (8)

Country Link
US (1) US7101551B2 (de)
EP (1) EP1256348B1 (de)
KR (1) KR20020091093A (de)
CN (1) CN100391469C (de)
AT (1) ATE555794T1 (de)
AU (1) AU2001232267A1 (de)
BR (1) BR0108499A (de)
WO (1) WO2001058459A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7261893B2 (en) * 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
ES2363770T3 (es) * 2003-08-28 2011-08-16 Dainippon Sumitomo Pharma Co., Ltd. Preventivo o remedio para enfermedades inflamatorias del intestino que contiene anticuerpo anti-cd81 como principio activo.
JP4654418B2 (ja) * 2004-03-31 2011-03-23 独立行政法人産業技術総合研究所 上皮系細胞増殖促進剤
MX2007012569A (es) 2005-04-18 2007-12-06 Micromet Ag Neutralizadores de anticuerpos del factor estimulante de la colonia de macrofagos-granulocitos humanos.
CN102076713B (zh) * 2008-05-02 2015-03-25 诺华股份有限公司 改进的基于纤连蛋白的结合分子及其用途
US9139825B2 (en) 2009-10-30 2015-09-22 Novartis Ag Universal fibronectin type III bottom-side binding domain libraries
CA2800734A1 (en) 2010-05-25 2011-12-01 Universite De Strasbourg Combination of anti-envelope antibodies and anti-receptor antibodies for the treatment and prevention of hcv infection
EP2650367A4 (de) * 2010-12-06 2015-07-08 Sumitomo Dainippon Pharma Co Ltd Menschlicher monoklonaler antikörper
WO2013024157A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of host targeting agents for the treatment and the prevention of hcv infection
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
WO2013024155A1 (en) 2011-08-17 2013-02-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
WO2014033266A1 (en) 2012-08-31 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
RU2714919C2 (ru) 2013-08-30 2020-02-21 Такеда Гмбх Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков
WO2015188141A2 (en) * 2014-06-06 2015-12-10 Memorial Sloan-Kettering Cancer Ceneter Mesothelin-targeted chimeric antigen receptors and uses thereof
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
JP7072715B2 (ja) 2018-07-20 2022-05-20 サーフィス オンコロジー インコーポレイテッド 抗ｃｄ１１２ｒ組成物及び方法
MX2021005048A (es) 2018-10-31 2021-09-08 Bioatla Inc Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574132A (en) * 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
EP0697888B1 (de) * 1993-05-12 2003-09-17 Chiron Corporation Konserviertes Motiv der Hepatitis C Virus E2/NS1 Region
CN1044384C (zh) * 1994-08-25 1999-07-28 中国药品生物制品检定所 抗丙型肝炎病毒抗原单克隆抗体细胞株建立及其单克隆抗体
CN1072482C (zh) 1996-11-08 2001-10-10 山东医科大学 低分子肝素脂质体喷胶剂及制备工艺
WO1999018198A1 (en) * 1997-10-06 1999-04-15 Chiron S.P.A. Hepatitis c receptor protein cd81
JP4593783B2 (ja) 1998-07-21 2010-12-08 ゲンマブ・アクティーゼルスカブ 抗ｃ型肝炎ウイルス抗体およびその使用
WO2000026418A1 (en) 1998-11-05 2000-05-11 The Board Of Trustees Of Leland Stanford Junior University Human pan-hcv human monoclonal antibodies
EP1293564A4 (de) 2000-06-08 2005-08-17 Mitsubishi Pharma Corp Expressionsvektor zum screenen von zellen mit hoher expression von rekombinanten proteinen, transformand mit hoher expression eines rekombinanten proteins und dessen verwendung

Also Published As

Publication number Publication date
WO2001058459A1 (fr) 2001-08-16
CN1423561A (zh) 2003-06-11
EP1256348A4 (de) 2005-07-27
US20030157132A1 (en) 2003-08-21
CN100391469C (zh) 2008-06-04
EP1256348B1 (de) 2012-05-02
US7101551B2 (en) 2006-09-05
EP1256348A1 (de) 2002-11-13
KR20020091093A (ko) 2002-12-05
BR0108499A (pt) 2003-03-11
AU2001232267A1 (en) 2001-08-20

Similar Documents

Publication Publication Date Title
EP1256348A4 (de) Heilmittel gegen hepatitis
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
WO2006033995A3 (en) Thiazolidin-4-ones having anti-hepatitis b activity
PT1169339E (pt) Peptidos macrociclicos activos contra o virus da hepatite c
DE50102597D1 (de) Arzneimittel gegen virale erkrankungen
EA200700243A1 (ru) Способы лечения гепатита с
EP1673385A4 (de) Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus
NO20051969L (no) Nukleosidderivater for behandling av hepatitt C virusinfeksjon.
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
GEP20104956B (en) Compounds for inhibiting hepatitis c viral replication and use thereof
WO2007001406A3 (en) Aryl-containing macrocyclic compounds
WO2001077091A3 (en) Ns5b hcv polymerase inhibitors
EA200501689A1 (ru) Соединения в качестве ингибиторов вируса гепатита c
WO2009039246A3 (en) Methods of treating a flaviviridae family viral infection, compositions for treating a flaviviridae family viral infection, and screening assays for identifying compositions for treating a flaviviridae family viral infection
ECSP045300A (es) Antígenos virales
ID27457A (id) Komposisi untuk pengobatan hiv dan infeksi virus lainnya
EP1730167A4 (de) Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus
BR0305259A (pt) Inibidores de hcv ns5b polimerase
WO2007084413A3 (en) Methods for treating hepatitis c
PY0111577A (es) Métodos y composiciones para el tratamiento del virus de la hepatitis c
UY28581A1 (es) Compuestos nucleosidicos para el tratamiento de infecciones virales
DK1387681T3 (da) Anvendelse af castanosperinderivater til behandling af hepatitis C
PT1299395E (pt) Oxazinoquinolonas uteis para o tratamento de infeccoes provocadas por virus
WO2002062959A3 (en) Hepatitis b virus treatment
NO20033829L (no) Virusdrepende preparater